(Q37120655)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18370477%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

title

The cost-effectiveness of clozapine: a survey of the literature (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18370477%20AND%20SRC:MED&resulttype=core&format=json

cost-effectiveness analysis

4 January 2020

main subject

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18370477%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Alistair McGuire

3

0 references

author name string

Thomas Hogan

series ordinal

2

0 references

publication date

1 January 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18370477%20AND%20SRC:MED&resulttype=core&format=json

Clinical Drug Investigation

4 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18370477%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18370477%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18370477%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

page(s)

137-152

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18370477%20AND%20SRC:MED&resulttype=core&format=json

The decision rules of cost-effectiveness analysis

4 January 2020

cites work

1 reference

12 December 2020

Effects of the clozapine national registry system on incidence of deaths related to agranulocytosis

1 reference

12 December 2020

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

1 reference

12 December 2020

G-CSF and the management of clozapine-induced agranulocytosis

1 reference

12 December 2020

Savings in hospital bed-days related to treatment with clozapine.

1 reference

12 December 2020

Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia.

1 reference

12 December 2020

Clozapine's cost effectiveness.

1 reference

12 December 2020

Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients.

1 reference

12 December 2020

Clozapine's cost-benefits

1 reference

12 December 2020

Cost-effectiveness of clozapine. A UK clinic-based study

1 reference

12 December 2020

A two-year clinical and economic follow-up of patients on clozapine

1 reference

12 December 2020

The pharmacoeconomics of clozapine: a review.

1 reference

12 December 2020

Towards more effective antipsychotic treatment.

1 reference

12 December 2020

Clinical efficacy of clozapine in treatment-refractory schizophrenia: an overview

1 reference

12 December 2020

A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

1 reference

12 December 2020

Clozapine-induced agranulocytosis. Incidence and risk factors in the United States

1 reference

12 December 2020

Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment

1 reference

12 December 2020

Cost-effectiveness of clozapine treatment in therapy-refractory schizophrenia.

1 reference

12 December 2020

Mortality in current and former users of clozapine.

1 reference

12 December 2020

Clozapine's effectiveness for patients in state hospitals: results from a randomized trial.

1 reference

12 December 2020

Disabilities and circumstances of schizophrenic patients--a follow-up study. Cause of death

1 reference

12 December 2020

Clozapine's cost effectiveness

1 reference

12 December 2020

Long-term clinical and social outcome studies in schizophrenia in relation to the cognitive and emotional side effects of antipsychotic drugs.

1 reference

12 December 2020

Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom.

1 reference

12 December 2020

Schizophrenia: a life-shortening disease

1 reference

12 December 2020

Economics and schizophrenia: the real cost.

1 reference

12 December 2020

Dimensions of outcome with clozapine

1 reference

12 December 2020

Clozapine's cost effectiveness

1 reference

12 December 2020

Mortality in schizophrenia--the Iowa Record-Linkage Study: a comparison with general population mortality.

1 reference

12 December 2020

Mortality in a cohort of patients with schizophrenia: a record linkage study

1 reference

12 December 2020

10.2165/00044011-199815020-00007

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18370477%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

1 reference